NeoGenomics, Inc. (NEO)

Market Cap	1.57B
Revenue (ttm)	551.62M
Net Income (ttm)	-114.67M
Shares Out	127.55M
EPS (ttm)	-0.92
PE Ratio	n/a
Forward PE	222.22
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,478,838
Open	12.67
Previous Close	12.51
Day's Range	11.90 - 12.68
52-Week Range	6.00 - 20.54
Beta	1.08
Analysts	Buy
Price Target	19.33 (+57.15%)
Earnings Date	Nov 7, 2023

About NEO

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence ...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Nov 2, 1999
• Employees: 2,100
• Stock Exchange: NASDAQ
• Ticker Symbol: NEO

Financial Performance

In 2022, NeoGenomics's revenue was $509.73 million, an increase of 5.24% compared to the previous year's $484.33 million. Losses were -$144.25 million, 1628.2% more than in 2021.

Analyst Forecast

According to 10 analysts, the average rating for NEO stock is "Buy." The 12-month stock price forecast is $19.33, which is an increase of 57.15% from the latest price.

Price Target

$19.33

(57.15% upside)

Analyst Consensus: Buy